CY2168B1 - Fusion proteins their preparation and use - Google Patents

Fusion proteins their preparation and use

Info

Publication number
CY2168B1
CY2168B1 CY0000013A CY0000013A CY2168B1 CY 2168 B1 CY2168 B1 CY 2168B1 CY 0000013 A CY0000013 A CY 0000013A CY 0000013 A CY0000013 A CY 0000013A CY 2168 B1 CY2168 B1 CY 2168B1
Authority
CY
Cyprus
Prior art keywords
fusion proteins
manner
preparation
fusion protein
oligonucleotide
Prior art date
Application number
CY0000013A
Other languages
English (en)
Inventor
Siegfried Stengelin
Wolfgang Ulmer
Paul Habermann
Eugen Uhlmann
Brian Seed
Original Assignee
Gen Hospital Corp
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Aventis Pharma Gmbh filed Critical Gen Hospital Corp
Publication of CY2168B1 publication Critical patent/CY2168B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY0000013A 1989-08-29 2000-05-03 Fusion proteins their preparation and use CY2168B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39987489A 1989-08-29 1989-08-29

Publications (1)

Publication Number Publication Date
CY2168B1 true CY2168B1 (en) 2002-08-23

Family

ID=23581315

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0000013A CY2168B1 (en) 1989-08-29 2000-05-03 Fusion proteins their preparation and use

Country Status (19)

Country Link
EP (1) EP0489780B1 (de)
JP (1) JP3043803B2 (de)
KR (1) KR0159786B1 (de)
AT (1) ATE173018T1 (de)
AU (1) AU638277B2 (de)
CA (1) CA2065146C (de)
CY (1) CY2168B1 (de)
DE (1) DE69032743T2 (de)
DK (1) DK0489780T3 (de)
ES (1) ES2124216T3 (de)
FI (1) FI113183B (de)
GR (1) GR1005153B (de)
HU (1) HU216069B (de)
IE (1) IE903120A1 (de)
IL (1) IL95495A (de)
NO (1) NO308667B1 (de)
PT (1) PT95111B (de)
WO (1) WO1991003550A1 (de)
ZA (1) ZA906839B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426036A (en) * 1987-05-05 1995-06-20 Hoechst Aktiengesellschaft Processes for the preparation of foreign proteins in streptomycetes
SG46612A1 (en) * 1992-12-02 1998-02-20 Hoechst Ag Process for obtaining proinsulin in processing correctly linked cystine bridges
DK0622376T3 (da) * 1993-04-27 2001-11-12 Hoechst Ag Amorfe monosfæriske former af insulinderivater
DE69435058T2 (de) * 1993-10-05 2008-04-30 Asahi Glass Co., Ltd. Multicloning-vektor, expressionsvektor und herstellung von fremdproteinen unter verwendung des expressionsvektors
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
DE59711533D1 (de) 1996-07-26 2004-05-27 Aventis Pharma Gmbh Insulinderivate mit erhöhter Zinkbindung
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE19915938A1 (de) 1999-04-09 2000-10-19 Aventis Pharma Gmbh Herstellung von pankreatischer Procarboxypeptidase B, Isoformen und Muteinen davon und ihre Verwendung
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
EP1563075A4 (de) * 2002-11-12 2006-09-06 Ckd Bio Corp Humaninsulin exprimierende plasmide und verfahren zur herstellung von humaninsulin damit
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
BRPI0907119A2 (pt) 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
PL2739646T3 (pl) 2011-05-10 2018-05-30 Stefan Hermann Kompleksowy układ buforowy do renaturacji ludzkiej proinsuliny lub pochodnych proinsuliny
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
JP5858945B2 (ja) 2012-03-15 2016-02-10 アークレイ株式会社 酵素を用いた測定方法
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10660852B2 (en) * 2015-09-18 2020-05-26 Bionet Pharma Gmbh Expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein
JP7460182B2 (ja) * 2019-02-19 2024-04-02 ザ、トラスティーズ オブ プリンストン ユニバーシティ フォールディングされたドメインおよびｒｎａ顆粒会合タンパク質ドメインの光制御オリゴマー化および相分離のためのシステムおよび方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4431739A (en) * 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
EP0195680A3 (de) * 1985-03-21 1987-06-10 Immunex Corporation Proteinsynthese mit einem Identifizierungspeptid
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
IE903120A1 (en) 1991-03-13
GR900100635A (el) 1991-12-30
HK1012026A1 (en) 1999-07-23
EP0489780A1 (de) 1992-06-17
IL95495A (en) 1996-10-16
KR0159786B1 (ko) 1998-11-16
NO308667B1 (no) 2000-10-09
AU638277B2 (en) 1993-06-24
PT95111B (pt) 1998-10-30
JPH05501799A (ja) 1993-04-08
NO920774L (no) 1992-04-28
EP0489780B1 (de) 1998-11-04
FI920923A0 (fi) 1992-02-28
ES2124216T3 (es) 1999-02-01
FI113183B (fi) 2004-03-15
DE69032743T2 (de) 1999-06-17
WO1991003550A1 (en) 1991-03-21
AU6287290A (en) 1991-04-08
PT95111A (pt) 1991-05-22
IL95495A0 (en) 1991-06-30
GR1005153B (el) 2006-03-13
DE69032743D1 (de) 1998-12-10
HUT60327A (en) 1992-08-28
EP0489780A4 (en) 1992-08-12
DK0489780T3 (da) 1999-07-19
JP3043803B2 (ja) 2000-05-22
NO920774D0 (no) 1992-02-27
CA2065146A1 (en) 1991-03-01
ZA906839B (en) 1991-06-26
ATE173018T1 (de) 1998-11-15
HU216069B (hu) 1999-04-28
HU9200674D0 (en) 1992-08-28
CA2065146C (en) 2002-07-23

Similar Documents

Publication Publication Date Title
GR900100635A (el) Πρωτεϊνες συντήξεως, παρασκευή τους και χρήση τους.
ATE88501T1 (de) Rekombinante dns-expressionsvektoren.
AU6569386A (en) Eukaryotic fusion proteins, the preparation and use thereof and means for carrying out the process
RU93045577A (ru) Слитные полипептиды
YU113285A (en) Process for making necrosis tumor factor from mixture with other proteins
YU86883A (en) Process for producing functional human urochinase proteins
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
AU3461797A (en) Fas ligand-like protein, its production and use
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
NZ233450A (en) Cdna sequence encoding lactoferrin and its use in production of lactoferrin
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
EP0431541A3 (en) Toxoplasma gondii antigen, its production and use
IL79805A0 (en) Production of pluripotent granulocyte colony-stimulating factor
ATE419357T1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
NZ292565A (en) Production of stabilised complement protein-3 convertase
DE3377917D1 (en) Dna fragments encoding for an immunogenic peptide capable of inducing in vivo synthesis of anti-polio virus antibodies
ATE295890T1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
ES553374A0 (es) Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes.
GR3036312T3 (en) Polypeptides and dna encoding same, associated with human malaria parasites.
IT1243286B (it) Processo per isolamento ed espressione del fattore neuronotrofico ciliare umano mediante la tecnologia del dna ricombinante.
JPS6474988A (en) Synthetic gene of cystatin c, corresponding recombinant plasmid and recombinant
MX9707244A (es) Expresion de genes en celulas de mamifero.